Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (PREDICT)

Trial Profile

Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (PREDICT)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms PREDICT
  • Sponsors Allergan
  • Most Recent Events

    • 01 Jul 2018 Primary endpoint (Change from Baseline in Migraine-Specific Quality of Life (MSQ) at Treatment 4 Using a 6-Item Questionnaire) has been met, according to the results presented at the 60th Annual Scientific Meeting of the American Headache Society
    • 01 Jul 2018 Interim results presented at the 60th Annual Scientific Meeting of the American Headache Society
    • 28 Jun 2018 According to Allergan Media release, data from this trial will be presented at the American Headache Society's 60th Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top